OraSure Technologies, Inc. (OSUR)
OraSure Technologies develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices globally. Their focus is on infectious disease testing and molecular solutions.
Company Overview
OraSure Technologies pioneers oral fluid diagnostics, offering innovative solutions like the InteliSwab COVID-19 test and OraQuick HIV test, targeting diverse markets from clinical labs to home use, and driving growth in infectious disease and molecular testing worldwide.
Investment Thesis
OraSure Technologies presents a compelling investment opportunity driven by its innovative diagnostic solutions and expanding market reach. While currently unprofitable with a P/E of -3.28 and a negative profit margin of -47.9%, the company's gross margin of 40.4% indicates potential for improved profitability with scale. Key value drivers include the continued demand for COVID-19 testing, growth in HIV self-testing, and expansion of its molecular solutions business. Upcoming catalysts include potential new product approvals and partnerships. Investors should consider the company's strong market position in oral fluid diagnostics and its potential to capitalize on the growing demand for convenient and accurate testing solutions. The company's beta of 0.91 suggests lower volatility than the overall market.
Key Highlights
- Market capitalization of $0.20 billion reflects the company's current valuation in the market.
- Gross margin of 40.4% demonstrates the company's ability to generate revenue above its cost of goods sold.
- P/E ratio of -3.28 indicates the company is currently unprofitable.
- Beta of 0.91 suggests the stock price is slightly less volatile than the overall market.
- The company operates in two segments, Diagnostics and Molecular Solutions, diversifying its revenue streams.
Competitors
Strengths
- Innovative oral fluid collection technology
- Established market presence in HIV testing
- Diverse product portfolio
- Global distribution network
Weaknesses
- Current lack of profitability
- Dependence on COVID-19 testing demand
- Limited market share in some segments
- High operating expenses
Catalysts
- Upcoming: Potential new product approvals for infectious disease diagnostics.
- Ongoing: Expansion of the molecular solutions business through partnerships.
- Ongoing: Increased adoption of HIV self-testing in key markets.
Risks
- Potential: Decline in COVID-19 testing demand as the pandemic subsides.
- Ongoing: Competition from larger diagnostic companies.
- Potential: Regulatory hurdles for new product approvals.
- Ongoing: Economic downturn impacting healthcare spending.
Growth Opportunities
- Expansion of Molecular Solutions: OraSure can leverage its Oragene and ORAcollect brands to capitalize on the growing market for genomic and microbiome testing. The global genomics market is projected to reach billions of dollars in the coming years, driven by advancements in personalized medicine and increasing demand for genetic testing services. By expanding its offerings and partnerships in this space, OraSure can tap into a high-growth market segment.
- Increased Adoption of HIV Self-Testing: The OraQuick In-Home HIV test offers a convenient and confidential testing option, addressing a critical need in HIV prevention and control. As awareness of HIV self-testing increases and regulatory barriers are reduced, OraSure can expand its market share by targeting at-risk populations and partnering with public health organizations. This aligns with global efforts to achieve HIV eradication goals.
- Geographic Expansion: OraSure has opportunities to expand its presence in international markets, particularly in developing countries where access to diagnostic testing is limited. By establishing partnerships with local distributors and healthcare providers, the company can introduce its products and address unmet needs in these regions. This can drive revenue growth and diversify its geographic footprint.
- New Product Development: OraSure can invest in research and development to expand its portfolio of diagnostic tests and specimen collection devices. This includes developing new tests for emerging infectious diseases, as well as improving the accuracy and ease of use of existing products. By staying at the forefront of innovation, OraSure can maintain its competitive advantage and capture new market opportunities.
- Strategic Acquisitions: OraSure can pursue strategic acquisitions to expand its product offerings, enter new markets, or acquire complementary technologies. This can accelerate its growth and enhance its competitive position in the diagnostic testing industry. Potential acquisition targets could include companies with expertise in molecular diagnostics, point-of-care testing, or specimen collection.
Opportunities
- Expansion into new geographic markets
- Development of new diagnostic tests
- Strategic acquisitions
- Increased adoption of self-testing
Threats
- Competition from established players
- Regulatory changes
- Pricing pressures
- Economic downturn
Competitive Advantages
- Patented oral fluid collection technology
- Established brand recognition in HIV testing
- Strong relationships with key distributors
- Expertise in infectious disease diagnostics
About
OraSure Technologies, Inc., founded in 2000 and headquartered in Bethlehem, Pennsylvania, is a leader in the development, manufacture, and marketing of oral fluid diagnostic products and specimen collection devices. The company operates through two segments: Diagnostics and Molecular Solutions. OraSure's evolution has been marked by a commitment to innovative testing solutions, beginning with its flagship OraQuick Rapid HIV test and expanding to a comprehensive portfolio that addresses critical healthcare needs. Their product line includes the InteliSwab COVID-19 rapid test series, catering to professional and at-home use, as well as tests for HCV and Ebola. Beyond infectious diseases, OraSure offers the Intercept drug testing system and Q.E.D. saliva alcohol test. The company's molecular solutions encompass Oragene and ORAcollect brands for genomic and microbiome collection, along with GenoFIND genomics laboratory services. OraSure serves a diverse customer base, including clinical laboratories, hospitals, government agencies, and commercial entities, across the United States, Europe, and internationally. Their competitive advantage lies in their patented oral fluid collection technology and established market presence in key diagnostic areas.
What They Do
- Develops oral fluid diagnostic products.
- Manufactures specimen collection devices.
- Markets diagnostic tests for infectious diseases.
- Provides genomic and microbiome collection products.
- Offers laboratory services for genomic testing.
- Sells COVID-19 rapid tests.
- Offers HIV self-testing solutions.
Business Model
- Sales of diagnostic tests to clinical laboratories and hospitals.
- Distribution of self-testing kits to consumers.
- Revenue from genomic laboratory services.
- Partnerships with government agencies and public health organizations.
Industry Context
OraSure Technologies operates within the medical instruments and supplies industry, a sector characterized by technological innovation and increasing demand for point-of-care diagnostics. The market is driven by factors such as the rising prevalence of infectious diseases, the growing adoption of self-testing, and advancements in molecular diagnostics. OraSure competes with companies like CATX, GNFT, NAUT, NTHI, and NYXH, each vying for market share in various segments of the diagnostic testing landscape. The industry is subject to regulatory oversight and pricing pressures, but also offers significant growth opportunities for companies with innovative and cost-effective solutions.
Key Customers
- Clinical laboratories
- Hospitals and clinics
- Government agencies
- Public health organizations
- Consumers
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $27M | -$14M | $0.00 |
| Q2 2025 | $31M | -$20M | $0.00 |
| Q1 2025 | $30M | -$16M | $0.00 |
| Q4 2024 | $37M | -$11M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
OraSure Technologies, Inc. (OSUR) stock price: $2.69 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in OSUR's future growth, indicating a belief in the company's potential.
- •Positive community sentiment has emerged, with discussions highlighting OSUR's innovative products and their market relevance.
- •Recent partnerships and collaborations have been viewed favorably, enhancing OSUR's market positioning and credibility.
- •The healthcare sector's ongoing demand for diagnostic solutions aligns well with OSUR's offerings, creating a favorable long-term outlook.
Why Bear
- •Concerns over regulatory challenges have surfaced, with some investors worried about potential delays in product approvals.
- •Community sentiment has shown skepticism regarding OSUR's ability to scale operations effectively amid increasing competition.
- •Recent earnings reports have raised questions about revenue consistency, leading to doubts about the company's growth trajectory.
- •Market perception has been tempered by broader economic uncertainties, which could impact OSUR's performance in the near term.
Latest News
-
Earnings Scheduled For November 5, 2025
benzinga · Nov 5, 2025
-
Earnings Scheduled For August 5, 2025
benzinga · Aug 5, 2025
-
Earnings Scheduled For May 7, 2025
benzinga · May 7, 2025
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · May 26, 2022
Technical Analysis
Rationale
AI-generated technical analysis for OSUR including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss OraSure Technologies, Inc. (OSUR) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for OSUR.
Make a Prediction
Set your price target for OraSure Technologies, Inc. (OSUR), choose a timeframe, and track your prediction accuracy.
Current price: $2.69
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OSUR.
Price Targets
Wall Street price target analysis for OSUR.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 2/100
Revenue declined -54.2% YoY, signaling shrinking demand or market headwinds.
-
Gross Margin 8/100
Gross margin at 40.6% indicates good unit economics and healthy profitability per sale.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates OSUR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does OraSure Technologies, Inc. do?
OraSure Technologies, Inc. is a global leader in the development, manufacture, and marketing of oral fluid diagnostic products and specimen collection devices. The company's core business revolves around providing innovative testing solutions for infectious diseases, including HIV, COVID-19, and HCV. Additionally, OraSure offers molecular solutions, such as genomic and microbiome collection products, and provides laboratory services for genomic testing. Their products are sold to clinical laboratories, hospitals, government agencies, and consumers, contributing to public health initiatives and individual healthcare management.
Is OSUR stock a good buy?
Assessing OSUR as a buy requires careful consideration of its financial metrics and growth prospects. While the company currently faces profitability challenges, its innovative product portfolio and market position in oral fluid diagnostics present potential for future growth. Investors should weigh the risks associated with declining COVID-19 testing demand and competition against the opportunities in expanding molecular solutions and HIV self-testing. Monitoring key metrics such as revenue growth, gross margin, and operating expenses will be crucial in determining the stock's long-term value.
What are the main risks for OSUR?
OraSure Technologies faces several key risks that investors should be aware of. A significant risk is the potential decline in demand for COVID-19 testing as the pandemic evolves. The company also faces competition from larger diagnostic companies with greater resources and market share. Regulatory changes and pricing pressures within the healthcare industry could also impact OraSure's profitability. Furthermore, an economic downturn could reduce healthcare spending and negatively affect demand for the company's products and services.
Is OSUR a good stock to buy?
Whether OSUR is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the OSUR MoonshotScore?
The MoonshotScore for OSUR is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is OSUR data updated?
OSUR stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to OSUR is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for OSUR?
Growth catalysts for OraSure Technologies, Inc. (OSUR) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes OraSure Technologies, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are OSUR's main competitors?
OraSure Technologies, Inc. (OSUR) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether OSUR has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about OSUR?
Wall Street analyst coverage for OSUR includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is OSUR's market cap?
Market capitalization (market cap) for OSUR is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows OSUR's current market cap alongside enterprise value and other valuation metrics.
How has OSUR stock performed recently?
OSUR's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing OSUR's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in OSUR?
Key risk categories for OSUR include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures OSUR's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling OSUR?
Insider trading activity for OSUR tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is OSUR a good stock for beginners?
OraSure Technologies, Inc. (OSUR) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is OSUR for first-time investors?
Every stock carries risk, including OraSure Technologies, Inc. (OSUR). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like OSUR.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Stock data pending update.
- Financial data based on the most recent available information.